MYGN Myriad Genetics Inc
- Stocks
- Healthcare
- NASDAQ: MYGN
Price (delayed)
$6.69
Market cap
$623.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.33
Enterprise value
$690.5M
Relative Growth:
Rel. Growth:
14
Relative Strength:
Rel. Strength:
52
Relative Valuation:
Rel. Valuation:
32
Relative Profitability:
Rel. Profitability:
15
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing
Highlights
The quick ratio has soared by 68% since the previous quarter and by 22% year-on-year
The company's equity fell by 49% YoY and by 3.9% QoQ
The debt has grown by 48% YoY and by 37% from the previous quarter
Key stats
What are the main financial stats of MYGN
Market
Valuations
Earnings
Shares outstanding
93.21M
Market cap
$623.6M
Enterprise value
$690.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
0.75
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.84
Revenue
$825.3M
Gross profit
$580.7M
Operating income
-$420.5M
Net income
-$400.5M
EBIT
-$418.5M
EBITDA
-$353.2M
Free cash flow
-$29.5M
Per share
Balance sheet
Liquidity
EPS
-$4.33
EPS diluted
-$4.33
Free cash flow per share
-$0.32
Book value per share
$4.01
Revenue per share
$8.86
TBVPS
$5.51
Total assets
$728.1M
Total liabilities
$355.3M
Debt
$212.3M
Equity
$372.8M
Working capital
$196.8M
Debt to equity
0.57
Current ratio
2.33
Quick ratio
1.78
Net debt/EBITDA
-0.19
Margins
Efficiency
Dividend
EBITDA margin
-42.8%
Gross margin
70.4%
Net margin
-48.5%
Operating margin
-51%
Return on assets
-46.6%
Return on equity
-73.9%
Return on invested capital
-111.8%
Return on capital employed
-72.1%
Return on sales
-50.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MYGN stock price
How has the Myriad Genetics stock price performed over time
Intraday
1.67%
1 week
-15.85%
1 month
-16.27%
1 year
-61.92%
YTD
-51.2%
QTD
-7.47%
Financial performance
How have Myriad Genetics's revenue and profit performed over time
Revenue
$825.3M
Gross profit
$580.7M
Operating income
-$420.5M
Net income
-$400.5M
Gross margin
70.4%
Net margin
-48.5%
The net margin has contracted by 2.3% from the previous quarter
Price vs fundamentals
How does MYGN's price correlate with its fundamentals
Growth
What is Myriad Genetics's growth rate over time
Valuation
What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.67
P/S
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.84
The company's equity fell by 49% YoY and by 3.9% QoQ
MYGN's price to book (P/B) is 22% lower than its 5-year quarterly average of 2.1 but 9% higher than its last 4 quarters average of 1.5
The P/S is 69% lower than the 5-year quarterly average of 2.4 and 26% lower than the last 4 quarters average of 1.0
Efficiency
How efficient is Myriad Genetics business performance
MYGN's return on equity is down by 18% since the previous quarter
Myriad Genetics's return on assets has decreased by 12% QoQ
The return on invested capital has grown by 3.5% since the previous quarter
Dividends
What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MYGN.
Financial health
How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 105% more than its total liabilities
The quick ratio has soared by 68% since the previous quarter and by 22% year-on-year
Myriad Genetics's current ratio has soared by 64% from the previous quarter and by 23% YoY
The debt is 43% less than the equity
The debt to equity has soared by 185% year-on-year and by 43% since the previous quarter
The company's equity fell by 49% YoY and by 3.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.